secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001654954-24-006912
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule
-----------------------------------------------------------------------------

- Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.
- Provided additional information and as of May 24, 2024, the Company has regained compliance and the matter is closed.
- No further action required; common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424006912/0001654954-24-006912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424006912/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-006912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer